An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Vor to Participate in Two Upcoming Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that members of its senior management team will be participating virtually in two upcoming investor conferences:
BofA Securities 2022 Healthcare Conference Date: Friday, May 13, 2022 Virtual 1x1 meetings only
H.C. Wainwright Global Investment Conference Presentation date: Tuesday, May 24, 2022 Pre-recorded on-demand presentation available beginning at 7:00 AM ET
The on-demand webcast of the presentation at the H.C. Wainwright Global Investment Conference be available on the Company's website at www.vorbio.com. An archived replay of the webcast will also be available.
About Vor Bio Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.
vor biopharma is pioneering engineered hematopoietic stem cells (ehscs) to dramatically change the treatment paradigm for hematological cancers. vor’s ehscs are designed to generate healthy, fully functional cells with specific advantageous modifications, for example to protect the blood and bone marrow from the toxic effects of antigen-targeted therapies, protecting healthy cells from depletion but leaving tumor cells vulnerable. vor’s platform could potentially be used to change the treatment paradigm of both hematopoietic stem cell transplants and antigen-targeted therapies such as antibody drug conjugates, bispecific antibodies and car-t cell treatments. a proof-of-concept study for vor’s lead program has been published in proceedings of the national academy of sciences. vor is based in cambridge, mass. and has a broad intellectual property base including in-licenses from columbia university, where foundational work was conducted by inventor and vor scientific board chair siddhar
